Інфаркт міокарда (біохімічні маркери)

24. Zioth Т., Hukman M., Halligren R., Roxiii L. Diagnosis size estimation and prediction of acute myocardial infarction from rnyoglobin observations. A system analysis to assess the influence of various souces of variability//Scand. J. Chn. and Lab. invest. - 1980 — № 155. — P. 111 — 124. {B}

{C}M. Bertrand, M. Simoons, K. Fox, Робоча група Європейського кардіологічного товариства

Матеріал підготував д. м. н. О.Й. Жарінов.

Литература:

1. E. Antman, R. Handin. Low–Molecular–Weight Heparins. An Intriguing New Twist With Profound Implications. Circulation 1998; 98: 287–289.

2. J. Hirsh, S. Anand, J. Halperin, V. Fuster. Guide to Anticoagulant Therapy: Heparin. A Statement for Healthcare Professionals From the American Heart Association. Circulation 2001; 103: 2994–3018.

3. U. Cornelli, J. Fareed. Human Pharmacokinetics of Low Molecular Weight Heparins. Sem Thormb Hemost 1999; 25 (suppl. 3): 57–61.

4. ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST–Segment Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). JACC 2000; 36: 970–1062.

5. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406–1432.

6. J. Cairns, P. Theroux, H. Lewis et al. Antithrombotic Agents in Coronary Artery Disease. In: Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001; 119 (suppl.): 228S–252S.

7. ACC/AHA/ACP–ASIM Guidelines for the Management of Patients With Chronic Stable Angina. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). JACC 1999; 33: 2092–2197.

8. ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Web Version.

9. ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines). A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). JACC 2001; 37: 2239i–2239lxvi.

10. S. Levy, G. Breithardt, R. Campbell et al.on behalf of the Working Group on Arrhythias of the European Society of Cardiology. Atrial fibrillation: current knowledge and recommendations for management. Eur Heart J 1998; 19: 1294–1320.

11. G. Albers, J. Dalen, A. Laupacis et.al. Antithrombotic Therapy in Atrial Fibrillation. Chest 2001; 119: 194S–206S.

12. G. Frostfeldt, G. Ahlberg, G. Gustafsson et al. Low Molecular Weight Heparin (Dalteparin) as Adjuvant Treatment to Thrombolysis in Acute Myocardial Infarction – A Pilot Study: Biochemical Markers of Acute Coronary Syndromes (BIOMACS II). JACC 1999; 33: 627–633.13. F. Kontny, J. Dale, U. Abildgaard et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. JACC 1997; 39: 962–969.

14. S. Baird, S. McBride, T. Trouton, C. Wilson. Low Molecular Weight Heparin Versus Unfractionated Heparin Following Thrombolysis in Myocardial Infarction. JACC 1998; 31 (suppl. 2A): 191A.

15. A. Glick, R. Kornowski, Y. Michowich et al. Reduction of reinfarction and angina with use of low–molecular–weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996; 77: 1145–1148.

16. A. Ross, P. Molhoek, C. Lundergan et al. Randomized Comparison of Enoxaparin Low–Molecular–Weight Heparin With Unfractionated Hepfrin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin Second Trial of Hepfrin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104: 648–652.

17. I. Menown, S. Baird, S. McBride et al. Evaluation of low–molecular–weight heparin in patients receiving fibrinolytic therapy for myocardial infarction. Eur Heart J 2000; 21 (abstr.suppl.): 599.

18. L. Wallentin, D. Dellborg, B. Nilsson et al. The Low–Molecular–Weight Heparin Dalteparin as Adjuvant Therapy in Acute Myocardial Infarction: the ASSENT PLUS study. Clin Cardiol 2001; 24 (suppl. I): I–12–14.